旗下有三精/哈藥/蓋中蓋/胃必治/護彤/世一堂等多個享譽市場的品牌,主營抗生素/非處方藥及保健品/傳統與現代中藥/生物醫藥/動物疫苗及醫藥商業等
哈藥(yao)(yao)集團有(you)(you)(you)(you)(you)限(xian)公(gong)(gong)(gong)司(si)(以下(xia)簡(jian)稱“哈藥(yao)(yao)集團”)為中(zhong)外合(he)資(zi)(zi)企(qi)業(ye)(ye)。哈爾濱(bin)市國資(zi)(zi)委持股(gu)(gu)(gu)(gu)(gu)38.25%,中(zhong)信(xin)資(zi)(zi)本冰(bing)島投(tou)資(zi)(zi)有(you)(you)(you)(you)(you)限(xian)公(gong)(gong)(gong)司(si)持股(gu)(gu)(gu)(gu)(gu)19.1%,華(hua)平冰(bing)島投(tou)資(zi)(zi)有(you)(you)(you)(you)(you)限(xian)公(gong)(gong)(gong)司(si)持股(gu)(gu)(gu)(gu)(gu)18.7%,哈爾濱(bin)國企(qi)重(zhong)組管理顧問有(you)(you)(you)(you)(you)限(xian)公(gong)(gong)(gong)司(si)持股(gu)(gu)(gu)(gu)(gu)8.5%,重(zhong)慶(qing)哈珀股(gu)(gu)(gu)(gu)(gu)權(quan)(quan)投(tou)資(zi)(zi)基金合(he)伙企(qi)業(ye)(ye)(有(you)(you)(you)(you)(you)限(xian)合(he)伙)持股(gu)(gu)(gu)(gu)(gu)10%,天津(jin)黑馬祺(qi)航投(tou)資(zi)(zi)管理有(you)(you)(you)(you)(you)限(xian)公(gong)(gong)(gong)司(si)持股(gu)(gu)(gu)(gu)(gu)5%,黑龍江中(zhong)信(xin)資(zi)(zi)本醫藥(yao)(yao)產業(ye)(ye)股(gu)(gu)(gu)(gu)(gu)權(quan)(quan)投(tou)資(zi)(zi)合(he)伙企(qi)業(ye)(ye)(有(you)(you)(you)(you)(you)限(xian)合(he)伙)持股(gu)(gu)(gu)(gu)(gu)0.425%。旗(qi)下(xia)擁(yong)有(you)(you)(you)(you)(you)哈藥(yao)(yao)股(gu)(gu)(gu)(gu)(gu)份(fen)(fen),人民同泰兩家上市公(gong)(gong)(gong)司(si)(截至2019年6月30日,哈藥(yao)(yao)集團持有(you)(you)(you)(you)(you)哈藥(yao)(yao)股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)46.49%股(gu)(gu)(gu)(gu)(gu)權(quan)(quan),哈藥(yao)(yao)股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)持有(you)(you)(you)(you)(you)人民同泰74.82%股(gu)(gu)(gu)(gu)(gu)權(quan)(quan))。旗(qi)下(xia)哈藥(yao)(yao)股(gu)(gu)(gu)(gu)(gu)份(fen)(fen)于2018年9月投(tou)資(zi)(zi)3億美(mei)(mei)元認購(gou)了美(mei)(mei)國保健(jian)品GNC發行(xing)的可轉換優先股(gu)(gu)(gu)(gu)(gu),轉股(gu)(gu)(gu)(gu)(gu)完(wan)成后,將(jiang)持有(you)(you)(you)(you)(you)GNC40.1%股(gu)(gu)(gu)(gu)(gu)權(quan)(quan),成為其單一大(da)股(gu)(gu)(gu)(gu)(gu)東。
集團擁有哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)總廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)三(san)(san)精(jing)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)六廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)中藥(yao)(yao)(yao)(yao)(yao)二廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)世一堂、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)生物(wu)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)三(san)(san)精(jing)四廠(chang)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)三(san)(san)精(jing)明水、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)三(san)(san)精(jing)千鶴、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)三(san)(san)精(jing)兒童(tong)、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)疫苗(miao)等11家工業(ye)企業(ye)和哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)人(ren)民同泰、哈(ha)(ha)藥(yao)(yao)(yao)(yao)(yao)營銷有限(xian)公司2家商業(ye)流通企業(ye)及1家藥(yao)(yao)(yao)(yao)(yao)物(wu)研究院。
集團主營涵蓋(gai)抗(kang)生(sheng)素(su)、非處方藥(yao)(yao)及保(bao)健(jian)品(pin)、傳統與(yu)現(xian)代中藥(yao)(yao)、生(sheng)物醫藥(yao)(yao)、動(dong)物疫苗及醫藥(yao)(yao)商業六(liu)大業務板塊(kuai)。哈藥(yao)(yao)股份有1816個藥(yao)(yao)品(pin)批文和74個保(bao)健(jian)食品(pin)批文。主導產品(pin)有葡(pu)萄(tao)糖酸鈣口(kou)服(fu)溶液(ye)、葡(pu)萄(tao)糖酸鋅口(kou)服(fu)溶液(ye)、阿莫西林膠囊、雙黃連口(kou)服(fu)液(ye)、前(qian)列地(di)爾注(zhu)射(she)液(ye)、小兒氨酚黃那(nei)敏顆(ke)粒(li)、拉西地(di)平片(pian)(pian)、注(zhu)射(she)用鹽(yan)酸頭孢替安(an)、布洛芬顆(ke)粒(li)、新蓋(gai)中蓋(gai)牌(pai)高鈣片(pian)(pian)等。截至2018年底,具備年產原料藥(yao)(yao)2200噸、化(hua)藥(yao)(yao)注(zhu)射(she)劑(ji)9.8億支、中藥(yao)(yao)注(zhu)射(she)劑(ji)1.8億支、口(kou)服(fu)液(ye)20億支、片(pian)(pian)劑(ji)120億片(pian)(pian)、膠囊131億粒(li)、化(hua)藥(yao)(yao)顆(ke)粒(li)劑(ji)12億袋的生(sheng)產能(neng)力。
所屬(shu)(shu)上(shang)市(shi)公(gong)司人(ren)民同泰主營醫(yi)(yi)(yi)藥批發和(he)零售(shou)業(ye)(ye)務,涵蓋(gai)(gai)中(zhong)(zhong)成(cheng)藥、中(zhong)(zhong)藥飲片、化學藥制劑、抗生素、生物制品(pin)、生化藥品(pin)、醫(yi)(yi)(yi)療(liao)器械(xie)及保健品(pin)等(deng)萬余(yu)個(ge)品(pin)規。有人(ren)民同泰醫(yi)(yi)(yi)藥連鎖店314家(jia),年營業(ye)(ye)額11.5億元。其(qi)下屬(shu)(shu)藥品(pin)批發企業(ye)(ye)與黑(hei)龍江省內(nei)1000多(duo)家(jia)醫(yi)(yi)(yi)療(liao)機構(gou),1900多(duo)家(jia)第(di)三終端,近700家(jia)商業(ye)(ye)客戶開展緊密合作,三級以(yi)上(shang)醫(yi)(yi)(yi)院的(de)(de)(de)市(shi)場(chang)覆蓋(gai)(gai)率95%以(yi)上(shang),二(er)級以(yi)上(shang)醫(yi)(yi)(yi)院的(de)(de)(de)市(shi)場(chang)覆蓋(gai)(gai)率達90%以(yi)上(shang)。其(qi)物流(liu)配送中(zhong)(zhong)心是黑(hei)龍江省、東北地區較大(da)的(de)(de)(de)現(xian)代(dai)化醫(yi)(yi)(yi)藥物流(liu)中(zhong)(zhong)心,儲(chu)存(cun)能(neng)力40萬箱,年吞吐能(neng)力300億元。根據(ju)商務部(bu)發布的(de)(de)(de)《2018年藥品(pin)流(liu)通(tong)行業(ye)(ye)運行統計(ji)分(fen)析報告》顯示,2018年人(ren)民同泰批發業(ye)(ye)務收(shou)入在全(quan)國藥品(pin)批發企業(ye)(ye)中(zhong)(zhong)排(pai)行第(di)27位(wei),零售(shou)業(ye)(ye)務銷售(shou)總(zong)額在全(quan)國零售(shou)企業(ye)(ye)中(zhong)(zhong)排(pai)行第(di)23位(wei)。
集(ji)團還(huan)擁有占(zhan)地(di)面積4萬平(ping)(ping)方米,建筑面積3.8萬平(ping)(ping)方米的新藥研發(fa)(fa)基地(di)——哈藥集(ji)團技術中(zhong)心,下(xia)設生物(wu)藥、化(hua)學(xue)原料藥、化(hua)學(xue)制劑、保健食品、質量檢測分(fen)析5個(ge)(ge)研發(fa)(fa)平(ping)(ping)臺,擁有發(fa)(fa)明授(shou)權專利(li)25件,近5年獲得(de)生產批件6個(ge)(ge),臨床批件17個(ge)(ge)。
截至2018年(nian)末,哈藥集團在職員(yuan)(yuan)工(gong)總數(shu)18618人(ren)(ren)(ren)。其中,正式員(yuan)(yuan)工(gong)15968人(ren)(ren)(ren),臨時用(yong)工(gong)人(ren)(ren)(ren)員(yuan)(yuan)2650人(ren)(ren)(ren)。擁(yong)有(you)中級以上(shang)職稱(cheng)的(de)3245人(ren)(ren)(ren),占正式員(yuan)(yuan)工(gong)的(de)20%;大學(xue)本科以上(shang)學(xue)歷的(de)4916人(ren)(ren)(ren),占正式員(yuan)(yuan)工(gong)的(de)31%,其中博士研究生11人(ren)(ren)(ren),碩(shuo)士研究生398人(ren)(ren)(ren)。
2018年,哈藥集團資產總額143.65億(yi)(yi)(yi)元(yuan)(yuan)(yuan)(yuan)(yuan);固定資產35.63億(yi)(yi)(yi)元(yuan)(yuan)(yuan)(yuan)(yuan);凈資產83.03億(yi)(yi)(yi)元(yuan)(yuan)(yuan)(yuan)(yuan);實現(xian)營業收入111.63億(yi)(yi)(yi)元(yuan)(yuan)(yuan)(yuan)(yuan);利潤總額6.36億(yi)(yi)(yi)元(yuan)(yuan)(yuan)(yuan)(yuan);凈利潤4.40億(yi)(yi)(yi)元(yuan)(yuan)(yuan)(yuan)(yuan),利稅13.11億(yi)(yi)(yi)元(yuan)(yuan)(yuan)(yuan)(yuan)。